For choosing axillary treatment, and adjuvant hormonal treatment

Breast Cancer ◽  
2015 ◽  
Vol 23 (2) ◽  
pp. 167-169
Author(s):  
Masakazu Toi ◽  
Shinji Ohno ◽  
Toshiaki Saeki ◽  
Seigo Nakamura ◽  
Beat Thürlimann
Keyword(s):  
Hormonal Treatment ◽  
Adjuvant Hormonal Treatment ◽  
Axillary Treatment

Survival outcome and treatment tolerability for postmenopausal females with early stage hormone receptor positive breast cancer treated with different adjuvant hormonal lines (TAM vs. AI vs. switching strategy) for 5 years

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Atef Youssef Riyad ◽  
Dalia Abdelghany Elkhodary ◽  
Wesam Reda Farag Elghamry ◽  
Islam Abdelrahman Kamel Mohamed Zaki
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitor ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors ◽  
Hormone Receptor ◽  
Disease Free Survival ◽  
Hormonal Treatment ◽  
Hormone Receptor Positive ◽  
Adjuvant Hormonal Treatment ◽  
Her 2

Abstract Background The standard adjuvant endocrine treatment for postmenopausal female patients with hormone receptor positive early breast cancer was 5 years of tamoxifen, but recurrence and side effects restrict its usefulness. The aromatase inhibitor (anastrozole or exemestane or letrozole) was compared with tamoxifen for 5 years or started after completing 2-3 years of tamoxifen in postmenopausal female patients diagnosed with early breast cancer at "Ain Shams University Hospitals" Objective The aim of the study was to measure survival outcome and treatment tolerability for postmenopausal females with Hormone Receptor Positive early breast cancer who received adjuvant hormonal treatment with tamoxifen [TAM] only for 5 years versus those who received adjuvant hormonal treatment with tamoxifen [TAM] for 2 years switching to aromatase inhibitors [AI] in the sequential 3 years versus those who received adjuvant hormonal treatment with aromatase inhibitors [AI] solely for 5 years. Patients and methods This study included 100 postmenopausal women with early breast cancer who presented at the Clinical Oncology Department, Ain Shams University, in the interval from January 2010 until December 2015. Conclusion Similar disease free survival and overall survival were observed among the three studied groups. Switching tamoxifen to aromatase inhibitors provides better tolerability in terms of endometrial thickness when compared to 5 years of tamoxifen monotherapy. Patients who administer aromatase inhibitor included in the switching strategy experience less osteoporosis and less generalized bone pain compared to upfront aromatase inhibitor to 5 years. There was a significant improvement of disease free survival (DFS) in human epidermal growth factor receptor 2 (HER 2) negative patients receiving any adjuvant hormonal treatment line for five years in comparison to HER 2 positive patients receiving the same adjuvant hormonal treatment for five years.

Use of mutational profiling of metastatic ER+/HER2- breast cancers and the coexistence of KRAS, MET, BRAF, and FGFR3 with PIK3CA mutations.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 11003-11003
Author(s):  
Debora Fumagalli ◽  
Roberto Salgado ◽  
Carmen Criscitiello ◽  
Lina Pugliano ◽  
Ioanna Laios ◽  
...  
Keyword(s):  
Hormonal Treatment ◽  
Primary Diagnosis ◽  
Outcome Data ◽  
Her2 Status ◽  
Breast Cancers ◽  
Genetic Changes ◽  
Pik3ca Mutations ◽  
Paired Samples ◽  
Adjuvant Hormonal Treatment ◽  
High Concordance

11003 Background: ER+/HER2- breast cancers (BCs) constitute the most frequent BC subtype. Their response to endocrine therapy and degree of estrogen dependence are heterogeneous. There is little data available about the genetic changes associated with disease progression in this subtype. This information could facilitate drug development. Methods: A series of 132 ER+/HER2- BC patients diagnosed between 1982 and 2008, with known local-regional (n=10) or distant (n=98) relapse or both (n=24), and available FFPE blocks from their primary (P; n=132) and paired relapse (R; n=49) were identified at a single institution. ER and HER2 status were centrally confirmed. 120 mutations from 11 actionable genes and PTEN protein expression were determined using Fluidigm-based real-time PCR and IHC, respectively. Results: At primary diagnosis, median age was 57 years (27-90); median tumor size 2.5 cm (0.5-11); 75% had positive nodes, 26.5% were pre-menopausal; 80% received adjuvant hormonal treatment. Mutation frequency in P and R samples is presented in the Table. PIK3CA mutations were identified in 44% (58/132) P samples. HRAS, AKT1 and PIK3CA mutations were mutually exclusive. 62.5% (5/8) of KRAS-mutated, 75% (6/8) of MET-mutated, 100% (2/2) of BRAF-mutated and 33.3% (1/3) of FGFR3-mutated P had coexistent PIK3CA mutations. For the 49 evaluated pairs, high concordance for the mutations status was found between P and R. Conclusions: KRAS, BRAF, MET and FGFR3 mutations, found at relatively high frequency in this population of relapsed ER+/HER2- BCs, could represent clinically relevant targets and contribute to mechanisms of recurrence, particularly in PIK3CA-mutated BCs. Mutation profiling of additional paired samples is ongoing and clinical outcome data will be presented. [Table: see text]

scholarly journals Effects of ‎tamoxifen on the reproductive system of female breast cancer patients: an ultrasound-based cohort study

F1000Research ◽  
2020 ◽  
Vol 9 ◽  
pp. 102
Author(s):  
Ghasak Kais Abd-Alhussain‎ ◽  
Mohammed Qasim Yahya Mal-Allah Alatrakji‎ ◽  
Wieeam Abdulfattah Saleh‎ ◽  
Hayder Adnan Fawzi ◽  
Aqeel‎ Shaker Mahmood‎
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Side Effects ◽  
Endometrial Thickness ◽  
Menopausal Status ◽  
Hormonal Treatment ◽  
Female Breast Cancer ◽  
Breast Cancer Patients ◽  
Er Positive ◽  
Adjuvant Hormonal Treatment

Background: Tamoxifen (TMX) is regarded as standard treatment for breast cancer (BC) patients‎. In recent years, several studies have reported gynecological side effects and due to TMX's estrogenic effects. Here, we evaluate the side effects of TMX on the ‎endometrium and ovaries of female BC patients. Methods: This was an ultrasound-based cohort study conducted in three oncology centers in Baghdad, Iraq. A total of ‎‎255 female patients were included, 140 premenopausal (PreM) and 115 postmenopausal (PostM), with estrogen receptor (ER)-positive BC using TMX adjuvant hormonal treatment for at least three months after surgery and adjuvant ‎chemo/radiotherapy.‎ Ultrasound (US) on the endometrium and ovaries of the women following ‎BC surgery/chemotherapy (baseline) and at 3, 6, 12, and 24 months following was performed‎. Data collected included age, menopausal status, co-morbid chronic illness and medications, including duration of TMX treatment. Results: Presence of ovarian cyst was significantly higher in the PreM ‎compared to PostM ‎women, while there were no significant differences for other gynecological findings.‎ At ‎baseline, endometrial thickness (ET) was significantly higher in the PreM compared to the PostM women. In both groups, women with increased ET became more frequent from baseline to 3 ‎months, from 3 to 6 ‎months, from 6 to 12 months, and from 12 ‎ to 24 months. At all time periods, ‎women with increased ET was ‎significantly higher in the PostM compared PreM women, resulting ‎in a risk of ET increase by 6 folds (ranging from 3 – ‎‎11 folds) ‎in PostM compared to PreM women. Conclusions: Longer duration of TMX is associated with increased ET. Duration of TMX did not appear to increase the risk of various gynecological outcomes, for example endometrial cancer rate was low. Finally, there was an increase in ET, which appeared to be six-folds higher in PostM compared to PreM women.‎

Adherence to adjuvant hormonal treatment for breast cancer in patients opting for local hospital direct drug distribution in Italy

2013 ◽  
Vol 20 (4) ◽  
pp. 232-235
Author(s):  
Marianna Rivasi ◽  
Raffaella Apollonio ◽  
Laura Cancian ◽  
Teresa Pilade ◽  
Mauro De Rosa
Keyword(s):  
Breast Cancer ◽  
Drug Distribution ◽  
Hormonal Treatment ◽  
Local Hospital ◽  
Adjuvant Hormonal Treatment

Update on adjuvant hormonal treatment of early breast cancer

2011 ◽  
Vol 28 (S6) ◽  
pp. 1-18 ◽  
Author(s):  
Juan Lao Romera ◽  
Teresa de Jesús Puertolas Hernández ◽  
Ignacio Peláez Fernández ◽  
Teresa Sampedro Gimeno ◽  
Roberto Fernández Martínez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Hormonal Treatment ◽  
Adjuvant Hormonal Treatment
Sign in / Sign up

Export Citation Format

Share Document